Study: ICD patients can exercise without errant shock risks; Adagio Medical raises $2.5M;

@FierceMedDev: Cardiac Science sells off diagnostic biz, focuses on defibrillators. News | Follow @FierceMedDev

@MarkHFierce: Folks have figured out a way to goose Dx tech that could enable personalized prostate cancer treatments. Release | Follow @MarkHFierce

 @DamianFierce: Now, per Reuters, Thermo Fisher is in the lead with a $12B bid on Life Tech. More | Follow @DamianFierce

> Acclarent, a division of Johnson & Johnson ($JNJ), got served with an FDA warning letter for changing a device's training materials without notifying the agency. Letter

> GnuBIO has launched beta versions of its desktop DNA sequencing system, which the company says is cheaper and faster than its competitors. Article

> Maine's NorDx is expanding its diagnostic capabilities with hematology analysis technology acquired from Japan's Sysmex. Release

> According to a new study, excercise doesn't raise the risk of errant shocks in heart failure patients implanted with ICDs. Story

> Sandia National Laboratories developed a diagnostic device--a lab on a disk--designed to screen for anthrax, ricin or other bioterror agents. Story

> T2 Biosystems has secured another patent to cover T2Candida, its blood diagnostic for the sepsis-causing infection. Item

> California startup Adagio Medical raised $2.5 million toward developing novel devices to treat cardiovascular disease. Story

Biotech News

@FierceBiotech: Elan closes $3.25B Tysabri deal and preps for biotech deal spree. News | Follow @FierceBiotech

@JohnCFierce: AstraZeneca's latest biotech deal offers more early-stage research work. Years away from PhIII, where it needs help. More | Follow @JohnCFierce.

@RyanMFierce: Pfizer made an another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce

> AstraZeneca gambles on cardio therapy in AlphaCore buyout. Report

> Resurgent Pfizer partners with Bind on new nanotech drug effort. News

> Biotech gamblers crowd high-stakes game for Sarepta. More

Pharma News

@FiercePharma: Tough German pricing authority backs Pfizer/BMS drug Eliquis as stroke preventive; 'significant' benefit. Report | Follow @FiercePharma

@EricPFierce: Lilly is installing some new technology in its US insulin cartridge plant, to pump up output. Article | Follow @EricPFierce

> Pfizer, Novartis eye bids for Brazil's Ache in deal worth $5B. Story

> South Africa's Adcock Ingram rebuffs buyout by conglomerate. More

> Valeant fires back at Merz with $415M-plus Obagi bid. News

Biomarkers News

 @EmilyMFierce: New prostate cancer predictors revealed. Report | Follow @EmilyMFierce

> CV biomarker study finds evidence of bias, exaggeration in the field. Story

> French researchers cast doubt on chemo biomarker's viability. Item

> Biomarkers predict risk of diabetes-related kidney trouble. Article

> U.K. team concocts rapid approach for colorectal cancer biomarker detection. More

Drug Delivery News

@MichaelGFierce: Biogen Idec's new oral MS drug Tecfidera has an unknown mechanism of action, the company says. More | Follow @MichaelGFierce

> Cholesterol 'rafts' enable cancer-killing delivery of DNA, RNA. Report

> Analysts expect nanotech drug delivery boom despite safety concerns. Story

> Pozen seeks FDA approval for layered aspirin cardiovascular treatment. Item

> FDA rejects A.P. Pharma's delayed-onset chemo drug. More

> Entrega, other startups make strides in needle-free delivery. Article

Suggested Articles

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.